Selinexor in relapsed/refractory multiple myeloma [PDF]
Therapeutic Advances in Hematology, 2020 Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and ...
Joshua Richter +3 more
doaj +6 more sources
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma [PDF]
Translational Oncology, 2017 Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz +4 more
doaj +4 more sources
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia [PDF]
Scientific Reports, 2023 Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including ...
Candida Vitale +13 more
doaj +3 more sources
Translational Oncology, 2021 Across many cancer types in adults, upregulation of the nuclear-to-cytoplasmic transport protein Exportin-1 (XPO1) correlates with poor outcome and responsiveness to selinexor, an FDA-approved XPO1 inhibitor.
Basia Galinski +2 more
exaly +3 more sources
XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma [PDF]
Frontiers in OncologyPurposeThe temozolomide (TMZ) resistance mechanisms in MGMT-promoter methylated IDH wildtype glioblastoma (GBM) tumors are poorly known. This study aimed to identify potential modulators of TMZ resistance in methylated GBM cells.MethodsA genome-wide ...
Josephine A. Mapunda +7 more
doaj +2 more sources
Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy [PDF]
Frontiers in OncologyBackgroundSelinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant incorporation into widespread ...
Muhamed Baljevic +4 more
doaj +2 more sources
Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method [PDF]
PharmaceuticsBackground/Objectives: Selinexor is a selective nuclear-export inhibitor approved for hematologic malignancies, characterized by extensive plasma protein binding (>95%). However, a validated analytical method to accurately measure the clinically relevant
Suhyun Lee +15 more
doaj +2 more sources
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo [PDF]
Antiviral Research, 2021 The novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the recent global pandemic. The nuclear export protein (XPO1) has a direct role in the export of SARS-CoV proteins
Jackelyn Murray, Bing Hou, Ralph A Tripp
exaly +3 more sources
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma [PDF]
British Journal of Haematology, 2019 Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/150566/1/bjh15969.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/150566/2/bjh15969_am ...
Andrzej J Jakubowiak +2 more
exaly +4 more sources
Journal of Hematology and Oncology, 2020 The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies ...
Zijun Y Xu-Monette +2 more
exaly +3 more sources